Ciprofloxacin as Therapy for Experimental Osteomyelitis Caused by Pseudomonas aeruginosa
- 1 February 1985
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 151 (2) , 291-294
- https://doi.org/10.1093/infdis/151.2.291
Abstract
Ciprofloxacin, a new carboxyquinoline antimicrobial agent, was compared with tobramycin in the treatment of chronic osteomyelitis due to Pseudomonas aeruginosa in rabbits. Treatment with tobramycin for four weeks was ineffective (94% had positive bone cultures). In contrast, ciprofloxacin administered for four weeks sterilized the bones of all but one (94%) of 18 treated rabbits. Treatment with ciprofloxacin for two weeks was less effective than treatment for four weeks but was more effective than either treatment with tobramycin or no therapy. Two of 10 isolates from rabbits treated with ciprofloxacin for two weeks were susceptible to MICs of ciprofloxacin that were 16- and fourfold greater than the MIC for the parent strain; the other eight isolates remained sensitive to ciprofloxacin with MICs equivalent to that of the parent strain.Keywords
This publication has 4 references indexed in Scilit:
- In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agentAntimicrobial Agents and Chemotherapy, 1984
- Activities of tobramycin and azlocillin alone and in combination against experimental osteomyelitis caused by Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 1982
- Experimental Osteomyelitis Caused by Pseudomonas aeruginosaThe Journal of Infectious Diseases, 1980
- Resistance to nalidixic acid. A misconception due to underdosageJAMA, 1976